Hubei Jumpcan Pharmaceutical Co Ltd (600566) — Cash Flow-to-Debt Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of CN¥-243.75 Million could theoretically repay 0% of its total liabilities (CN¥2.68 Billion) in one year. Explore 600566 long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hubei Jumpcan Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2000–2025)
Historical debt coverage capacity for Hubei Jumpcan Pharmaceutical Co Ltd across 26 annual periods. Also explore Hubei Jumpcan Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2000–2025)
Year-by-year debt coverage analysis for Hubei Jumpcan Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see market cap of Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | CN¥1.20 Billion | CN¥3.07 Billion | ▼ -33.0% |
| 2024 | 0.58x | CN¥2.18 Billion | CN¥3.73 Billion | ▼ -19.6% |
| 2023 | 0.73x | CN¥3.46 Billion | CN¥4.77 Billion | ▲ +0.4% |
| 2022 | 0.72x | CN¥2.62 Billion | CN¥3.63 Billion | ▲ +14.4% |
| 2021 | 0.63x | CN¥1.89 Billion | CN¥3.00 Billion | ▼ -2.4% |
| 2020 | 0.65x | CN¥1.78 Billion | CN¥2.75 Billion | ▼ -22.8% |
| 2019 | 0.84x | CN¥2.15 Billion | CN¥2.56 Billion | ▲ +14.8% |
| 2018 | 0.73x | CN¥1.71 Billion | CN¥2.34 Billion | ▲ +38.9% |
| 2017 | 0.53x | CN¥1.19 Billion | CN¥2.26 Billion | ▼ -25.1% |
| 2016 | 0.70x | CN¥913.10 Million | CN¥1.30 Billion | ▼ -5.1% |
| 2015 | 0.74x | CN¥645.48 Million | CN¥872.59 Million | ▲ +27.7% |
| 2014 | 0.58x | CN¥616.11 Million | CN¥1.06 Billion | ▲ +73.9% |
| 2013 | 0.33x | CN¥287.16 Million | CN¥862.04 Million | ▲ +519.2% |
| 2012 | 0.05x | CN¥27.01 Million | CN¥502.07 Million | ▲ +5590.6% |
| 2011 | 0.00x | CN¥411.24K | CN¥435.00 Million | ▼ -99.4% |
| 2010 | 0.15x | CN¥51.13 Million | CN¥342.89 Million | ▲ +880.6% |
| 2009 | 0.02x | CN¥4.92 Million | CN¥323.37 Million | ▼ -78.7% |
| 2008 | 0.07x | CN¥23.05 Million | CN¥323.43 Million | ▼ -41.1% |
| 2007 | 0.12x | CN¥36.72 Million | CN¥303.49 Million | ▲ +757.6% |
| 2006 | 0.01x | CN¥4.24 Million | CN¥300.69 Million | ▼ -94.4% |
| 2005 | 0.25x | CN¥63.38 Million | CN¥251.96 Million | ▲ +249.3% |
| 2004 | -0.17x | CN¥-37.74 Million | CN¥223.98 Million | ▼ -1481.1% |
| 2003 | 0.01x | CN¥2.24 Million | CN¥183.92 Million | ▼ -91.8% |
| 2002 | 0.15x | CN¥22.00 Million | CN¥148.17 Million | ▲ +166.1% |
| 2001 | 0.06x | CN¥7.43 Million | CN¥133.08 Million | ▼ -80.4% |
| 2000 | 0.28x | CN¥23.73 Million | CN¥83.37 Million | — |